NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 48 resultados LastUpdate Última actualización: 26/06/2016 [14:50:00] pdf PDF




Solicitudes de Patente publicadas en los últimos 30 días / Patent Applications published in the last 30 days



Página 1 de 2 nextPage   Mostrar por página


ANTHOCYANIDIN COMPLEX FOR THE TREATMENT OF MULTIPLE MYELOMA

Nº publicación: HK1212590A1 17/06/2016

Solicitante:
SAPIOTEC GMBH [DE]

Resumen de: WO2014060548A1

The subject matter of the invention is a complex of delphinidin and a sulfoalkyl ether ss-cyclodextrin for use as a medicinal drug, in particular in the treatment of multiple myeloma.



traducir


 

ANTHOCYANIDIN COMPLEX FOR THE TREATMENT OF MULTIPLE MYELOMA

Nº publicación: HK1212590A1 17/06/2016

Solicitante:
SAPIOTEC GMBH [DE]

Resumen de: WO2014060548A1

The subject matter of the invention is a complex of delphinidin and a sulfoalkyl ether ss-cyclodextrin for use as a medicinal drug, in particular in the treatment of multiple myeloma.



traducir


 

PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETROCYCLIC AMIDE COMPOUNDS AS ACTIVE INGREDIENT

Nº publicación: WO2016093255A1 16/06/2016

Solicitante:
ASTELLAS PHARMA INC [JP]

Resumen de: WO2016093255A1

[Problem] To provide a pharmaceutical composition for treating various cancers in which mitochondrial complex I is involved, in particular, colon cancer, leukemia and/or malignant lymphoma. [Solution] With the intention of creating pharmaceutical compositions for treating various cancers, the inventors confirmed, on the basis of the result of intensive investigation, that pharmaceutical compositions, which contain specific bicyclic nitrogen-containing aromatic heterocyclic amide compounds having an AMPK activation effect and mitochondrial complex I inhibition effect as active ingredients, have a therapeutic effect on various cancers in which mitochondrial complex I is involved, in particular, colon cancer, leukemia and/or malignant lymphoma, thereby completing the present invention.



traducir


 

PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE COMPONENT

Nº publicación: WO2016093203A1 16/06/2016

Solicitante:
ASTELLAS PHARMA INC [JP]

Resumen de: WO2016093203A1

[Problem] To provide a pharmaceutical composition for treating multiple myeloma. [Solution] After investigating compounds having a mitochondrial Complex I inhibitory effect, the present inventor completed the present invention by confirming that the bicyclic nitrogen-containing aromatic heterocyclic amide compounds of the present invention have a mitochondrial Complex I inhibitory effect, and that these compounds have a growth inhibition effect on multiple myeloma.



traducir


 

METHODS FOR DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA

Nº publicación: US2016169901A1 16/06/2016

Solicitante:
UNIV COLUMBIA [US]

Resumen de: US2016169901A1

The present invention is based, at least in part, on the discovery of biomarkers identified herein which are associated with cutaneous T-cell lymphoma (CTCL). Accordingly, the present invention provides methods for diagnosing CTCL, e.g., early stage CTCL, including mycosis fungoides (MF) and Sézary syndrome (SS), and to distinguish CTCL from other skin disorders.



traducir


 

TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE

Nº publicación: AU2016203386A1 16/06/2016

Solicitante:
VENTIRX PHARMACEUTICALS INC

Resumen de: US2010029585A1

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.



traducir


 

METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS

Nº publicación: AU2014360328A1 16/06/2016

Solicitante:
CELGENE CORP

Resumen de: WO2015085172A2

Provided herein, in some embodiments, are methods of using certain cereblon- associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.



traducir


 

METHODS FOR TREATING HEMATOLOGICAL CANCERS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNODULATORY THERAPIES

Nº publicación: AU2014360316A1 16/06/2016

Solicitante:
CELGENE CORP

Resumen de: WO2015085160A2

Provided herein, in certain embodiments, are biomarkers for use in predicting the clinical sensitivity of hematologic cancers, such as non-Hodgkin's lymphoma, and a patient's response to treatment with an immunomodulatory agent, such as 3-(4-anrino-l-oxo-l,3-dihydro-isoindol-2-y])-piperidine-2,6-dione, which is also known as lenalidomide or Revlimid TM . Also provided herein, in certain embodiments, are methods of treating or managing non-Hodgkin's lymphomas, including but not limited to diffuse large B-cell lymphoma (DLBCL), using prognostic factors.



traducir


 

COMBINATIONS FOR TREATING CANCERS

Nº publicación: US2016166579A1 16/06/2016

Solicitante:
GILEAD SCIENCES INC [US]

Resumen de: WO2016010862A1

Disclosed are combinations for treating a cancer in a subject (e.g., a human) in need thereof, comprising a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, and a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.



traducir


 

STABLE PHARMACEUTICAL COMPOSITION OF 5-AlphaZetaAlpha-2'RhoEpsilonOmicronChiUpsilonOmicronTauIotaRhoIotaNuEpsilon

Nº publicación: US2016166593A1 16/06/2016

Solicitante:
FRESENIUS KABI ONCOLOGY LTD [IN]

Resumen de: WO2014064717A1

The present invention relates to ready to use, non aqueous pharmaceutical compositions comprising 5-aza-2'deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. The present invention also relates to process for preparing pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes.



traducir


 

QUINOLINE DERIVATIVE

Nº publicación: US2016168121A1 16/06/2016

Solicitante:
ONO PHARMACEUTICAL CO [JP]

Resumen de: WO2015012298A1

A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeutic agent for Axl related diseases such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, cancer such as glioma, kidney disease, immune system disease, and circulatory system disease.



traducir


 

PURINONE COMPOUNDS AS KINASE INHIBITORS

Nº publicación: US2016168149A1 16/06/2016

Solicitante:
PHARMACYCLICS LLC [US]

Resumen de: WO2015002894A1

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.



traducir


 

METHODS FOR DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA

Nº publicación: US2016169901A1 16/06/2016

Solicitante:
UNIV COLUMBIA [US]

Resumen de: US2016169901A1

The present invention is based, at least in part, on the discovery of biomarkers identified herein which are associated with cutaneous T-cell lymphoma (CTCL). Accordingly, the present invention provides methods for diagnosing CTCL, e.g., early stage CTCL, including mycosis fungoides (MF) and Sézary syndrome (SS), and to distinguish CTCL from other skin disorders.



traducir


 

TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE

Nº publicación: AU2016203386A1 16/06/2016

Solicitante:
VENTIRX PHARMACEUTICALS INC

Resumen de: US2010029585A1

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.



traducir


 

PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETROCYCLIC AMIDE COMPOUNDS AS ACTIVE INGREDIENT

Nº publicación: WO2016093255A1 16/06/2016

Solicitante:
ASTELLAS PHARMA INC [JP]

Resumen de: WO2016093255A1

[Problem] To provide a pharmaceutical composition for treating various cancers in which mitochondrial complex I is involved, in particular, colon cancer, leukemia and/or malignant lymphoma. [Solution] With the intention of creating pharmaceutical compositions for treating various cancers, the inventors confirmed, on the basis of the result of intensive investigation, that pharmaceutical compositions, which contain specific bicyclic nitrogen-containing aromatic heterocyclic amide compounds having an AMPK activation effect and mitochondrial complex I inhibition effect as active ingredients, have a therapeutic effect on various cancers in which mitochondrial complex I is involved, in particular, colon cancer, leukemia and/or malignant lymphoma, thereby completing the present invention.



traducir


 

PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE COMPONENT

Nº publicación: WO2016093203A1 16/06/2016

Solicitante:
ASTELLAS PHARMA INC [JP]

Resumen de: WO2016093203A1

[Problem] To provide a pharmaceutical composition for treating multiple myeloma. [Solution] After investigating compounds having a mitochondrial Complex I inhibitory effect, the present inventor completed the present invention by confirming that the bicyclic nitrogen-containing aromatic heterocyclic amide compounds of the present invention have a mitochondrial Complex I inhibitory effect, and that these compounds have a growth inhibition effect on multiple myeloma.



traducir


 

METHODS FOR TREATING HEMATOLOGICAL CANCERS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNODULATORY THERAPIES

Nº publicación: AU2014360316A1 16/06/2016

Solicitante:
CELGENE CORP

Resumen de: WO2015085160A2

Provided herein, in certain embodiments, are biomarkers for use in predicting the clinical sensitivity of hematologic cancers, such as non-Hodgkin's lymphoma, and a patient's response to treatment with an immunomodulatory agent, such as 3-(4-anrino-l-oxo-l,3-dihydro-isoindol-2-y])-piperidine-2,6-dione, which is also known as lenalidomide or Revlimid TM . Also provided herein, in certain embodiments, are methods of treating or managing non-Hodgkin's lymphomas, including but not limited to diffuse large B-cell lymphoma (DLBCL), using prognostic factors.



traducir


 

METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS

Nº publicación: AU2014360328A1 16/06/2016

Solicitante:
CELGENE CORP

Resumen de: WO2015085172A2

Provided herein, in some embodiments, are methods of using certain cereblon- associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.



traducir


 

COMBINATIONS FOR TREATING CANCERS

Nº publicación: US2016166579A1 16/06/2016

Solicitante:
GILEAD SCIENCES INC [US]

Resumen de: WO2016010862A1

Disclosed are combinations for treating a cancer in a subject (e.g., a human) in need thereof, comprising a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, and a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.



traducir


 

STABLE PHARMACEUTICAL COMPOSITION OF 5-AlphaZetaAlpha-2'RhoEpsilonOmicronChiUpsilonOmicronTauIotaRhoIotaNuEpsilon

Nº publicación: US2016166593A1 16/06/2016

Solicitante:
FRESENIUS KABI ONCOLOGY LTD [IN]

Resumen de: WO2014064717A1

The present invention relates to ready to use, non aqueous pharmaceutical compositions comprising 5-aza-2'deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. The present invention also relates to process for preparing pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes.



traducir


 

QUINOLINE DERIVATIVE

Nº publicación: US2016168121A1 16/06/2016

Solicitante:
ONO PHARMACEUTICAL CO [JP]

Resumen de: WO2015012298A1

A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeutic agent for Axl related diseases such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, cancer such as glioma, kidney disease, immune system disease, and circulatory system disease.



traducir


 

PURINONE COMPOUNDS AS KINASE INHIBITORS

Nº publicación: US2016168149A1 16/06/2016

Solicitante:
PHARMACYCLICS LLC [US]

Resumen de: WO2015002894A1

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.



traducir


 

AN ANTIGEN ASSOCIATED WITH LUNG CANCERS AND LYMPHOMAS

Nº publicación: HK1185816A1 10/06/2016

Solicitante:
PHILOGEN SPA [IT]

Resumen de: WO2009013619A2

The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of lung cancer and lymphoma.



traducir


 

AN ANTIGEN ASSOCIATED WITH LUNG CANCERS AND LYMPHOMAS

Nº publicación: HK1185816A1 10/06/2016

Solicitante:
PHILOGEN SPA [IT]

Resumen de: WO2009013619A2

The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of lung cancer and lymphoma.



traducir


 

USE OF AN H4 AGONIST MOLECULE TO TREAT ACUTE LEUKEMIA

Nº publicación: US2016158219A1 09/06/2016

Solicitante:
CHRYSALIS PHARMA [FR]

Resumen de: US2015148538A1

The present invention relates to the use of new chemical substances, the levogyre and dextrogyre enantiomers of (AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2METHYLENEDIOXY-6,7 TETRAHYDRO-,2,3,4 ISOQUINOLEINE or tritoqualine, to treat acute myeloid or lymphoid leukemia, with the exception of type B leukemia.


traducir



 

Página 1 de 2 nextPage Mostrar por página

Volver